With the advent of 2023, comes the start of the industry’s next patent cliff, with five products that reached billions in sales at their peak set to lose US patent exclusivity during the year. Scrip takes a look into how the affected big pharma firms are preparing for anticipated market erosion and which generic and biosimilar companies are positioned to benefit the most.

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Former sales and marketing exec at Taro Pharmaceuticals is latest exec charged with participating in price fixing conspiracies.

Following the expiry of Perrigo’s 180-day exclusivity for its generic version of AndroGel, firms including Lupin and Teva have launched their own generic testosterone 1.62% gels in the US.